Page last updated: 2024-11-04

raloxifene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Raloxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone and lipid metabolism, but as an antagonist in breast and uterine tissue. It is used to prevent osteoporosis in postmenopausal women, to reduce the risk of invasive breast cancer in women at high risk, and to treat osteoporosis in men. Raloxifene is synthesized through a multi-step process involving several organic reactions. The compound has been shown to reduce bone resorption, increase bone mineral density, and improve lipid profiles. Its effects are mediated through its binding to estrogen receptors in various tissues, leading to different responses depending on the receptor subtype. Raloxifene is studied extensively due to its potential therapeutic benefits in preventing and treating osteoporosis, breast cancer, and other conditions related to estrogen deficiency. Its mechanism of action, safety, and efficacy are continually being investigated.'

raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5035
CHEMBL ID81
CHEBI ID8772
SCHEMBL ID6144
MeSH IDM0112968

Synonyms (134)

Synonym
BIDD:ER0216
BIDD:GT0795
gtpl2820
ly-139481
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone
PRESTWICK2_000862
NCGC00015889-02
cas-82640-04-8
NCGC00015889-01
lopac-r-1402
PRESTWICK3_000862
(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone
LOPAC0_001051
BPBIO1_000995
raloxifenum
raloxifeno
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone
CHEBI:8772 ,
ly 139481
C07228
84449-90-1
raloxifene
DB00481
(2-(4-hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone
CMAP_000032
hsdb 7460
raloxifenum [latin]
methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-
ccris 7129
raloxifeno [spanish]
raloxifene [inn:ban]
KBIO2_004929
KBIO2_007497
KBIOSS_002364
KBIO2_002361
KBIOGR_002361
KBIO3_002840
PRESTWICK0_000862
SPBIO_002824
PRESTWICK1_000862
BSPBIO_000903
SMP2_000095
NCGC00092353-02
ly139481
bdbm19441
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
cid_11071264
raloxifene, 6
chembl81 ,
2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol
HMS2089F06
NCGC00015889-07
[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone
[6-hydroxy-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone
eviden
raloxiphene
j22.982b ,
raxeto
eviden (tn)
D08465
raxeto (tn)
raloxifene (inn)
nsc-747974
nsc747974
[2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone
methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-
NCGC00015889-05
NCGC00092353-04
yx9162eo3i ,
nsc 747974
unii-yx9162eo3i
pharoxifene
dtxcid803550
cas-84449-90-1
tox21_202603
NCGC00260151-01
dtxsid3023550 ,
VU0155042-3
2-(4-hydroxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]benzoyl}-1-benzothiophen-6-ol
CCG-205128
NCGC00015889-06
NCGC00015889-08
NCGC00015889-04
NCGC00015889-10
raloxifene [hsdb]
raloxifene [vandf]
raloxifene [who-dd]
raloxifene [mi]
raloxifene [inn]
AKOS015896267
S5781
6-hydroxy-2-(4-hydroxyphenyl)-3-[4(2-piperidinoethoxy)benzoyl]benzo[b]thiophene
6-hydroxy-2-(4-hydoxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene
[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]-thiophene
6-hydroxy-2-(4-hydoxyphenyl)-3[-4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene
[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1piperidinyl)ethoxy]phenyl]methanone
[6-hydroxy-2-(4-hydroxyphenyl)benzo-[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
6-hydroxy-2-(4-hyroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene
[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2piperidinoethoxy)-benzoyl]benzo[b]thiophene
6-hydroxy-2-(4-hydroxyphenyl)-3[-4-(2-piperidinoethoxy)benzoyl]benzo [b]thiophene
6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl methanone
6-hydroxy-2-(4-hydroxyphenyl)-3[-4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene
6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene
[2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
6-hydroxy-2-(4-hydroxyphenyl)-3[-4-(2piperidinoethoxy)benzoyl]benzo[b]thiophene
SCHEMBL6144
AC-8399
HY-13738
CS-0007764
MRF-0000684
SBI-0051021.P002
mfcd00866415
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone
Q425223
FT-0674305
AS-35086
BCP09772
keoxifene; ly 139481;
BRD-K63828191-003-11-5
SDCCGSBI-0051021.P003
NCGC00015889-22
HMS3742O11
nsc761389
nsc-761389
[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; keoxifene; ly 139481; raloxifene; [2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone
A916152
[2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methanone; raloxifeno
EN300-58333
(6-hydroxy-2-(4-hydroxyphenyl)-benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone
raloxifenum (latin)
g03xc01
(6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl)(4-(2-piperidin-1-ylethoxy)phenyl)methanone

Research Excerpts

Actions

ExcerptReferenceRelevance
"Raloxifene was found to inhibit competitively when using DACA as a probe, and a previous report showed that raloxifene inhibited uncompetitively with other substrates."( Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
Barr, JT; Jones, JP, 2013
)
1.11

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic based optimisation of a novel series of indole-2-carboxamide antagonists of the cannabinoid CB(1) receptor is disclosed."( Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
Baker, J; Buchanan, KI; Carlyle, I; Clark, JK; Clarkson, TR; Cowley, PM; Deehan, M; Edwards, D; Kiyoi, Y; Martin, I; Osbourn, D; Walker, G; Ward, N; Wishart, G, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" In a pharmacokinetic experiment carried out in rats, 29 displayed an interesting profile, with a bioavailability of 49%."( Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Bischoff, SF; Buhl, T; Floersheim, P; Fournier, B; Geiser, M; Halleux, C; Kallen, J; Keller, H; Ramage, P; Renaud, J, 2005
)
0.33
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
bone density conservation agentAn agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.
estrogen receptor modulatorA substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure.
estrogen antagonistA compound which inhibits or antagonises the biosynthesis or actions of estrogens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
1-benzothiophenes
N-oxyethylpiperidine
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (134)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency19.95260.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency5.22760.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency5.22760.025120.237639.8107AID886
acetylcholinesteraseHomo sapiens (human)Potency9.04460.002541.796015,848.9004AID1347395; AID1347397; AID1347398; AID1347399
15-lipoxygenase, partialHomo sapiens (human)Potency39.81070.012610.691788.5700AID887
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency55.00153.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency14.53510.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency38.93810.173734.304761.8120AID1346859
ATAD5 protein, partialHomo sapiens (human)Potency16.35350.004110.890331.5287AID493107
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency12.58930.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency2.81840.35487.935539.8107AID624146
SMAD family member 3Homo sapiens (human)Potency38.93810.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency5.86330.000714.592883.7951AID1259369; AID1259392
ThrombopoietinHomo sapiens (human)Potency15.84890.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency47.25360.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743053; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency68.65940.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency0.81160.011212.4002100.0000AID1030; AID493210
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency7.80730.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency71.45200.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency47.99660.000417.946075.1148AID1346784; AID1346795
EWS/FLI fusion proteinHomo sapiens (human)Potency7.82860.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency60.93820.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency54.89990.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency30.32230.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency67.53050.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency55.00150.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency19.35080.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency11.30450.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743077; AID743078; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency42.97520.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency34.37480.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency22.09820.023723.228263.5986AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency68.65940.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.81450.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency58.96750.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.00390.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency68.65940.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency61.71270.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency57.195419.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency52.01080.057821.109761.2679AID1159526; AID1159528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency16.53110.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency22.53580.316212.443531.6228AID902; AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency8.15480.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.56740.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency0.23110.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID488953
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency8.78360.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency56.07740.042027.378961.6448AID743210; AID743228
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency5.01190.65619.452025.1189AID927
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency21.36390.00378.618923.2809AID2660; AID2667; AID2668
gemininHomo sapiens (human)Potency33.49830.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency12.52010.005612.367736.1254AID624032; AID624044
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.88540.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency37.68580.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency15.84890.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency8.80060.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.35480.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.00220.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency68.65940.002319.595674.0614AID651631; AID720552
Integrin beta-3Homo sapiens (human)Potency19.95260.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency19.95260.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.00220.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.56740.00638.235039.8107AID883
D(1A) dopamine receptorSus scrofa (pig)Potency23.28090.00378.108123.2809AID2667
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency5.01191.584913.004325.1189AID927
GABA theta subunitRattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency61.19270.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency44.68820.011912.222168.7989AID588378; AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.88541.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency33.80780.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phospholipase D2Homo sapiens (human)IC50 (µMol)7.60000.00611.159810.0000AID1801138; AID498478; AID498482
Aldehyde oxidase 1Mus musculus (house mouse)IC50 (µMol)0.50000.15002.25006.1000AID547839
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)2.08000.00312.16029.6000AID1872409
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)1.17800.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.61700.00000.887110.0000AID625218
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.04270.00000.723732.7000AID102598; AID102601; AID102611; AID103888; AID103918; AID1301303; AID1594508; AID1676109; AID1797853; AID1797989; AID1797992; AID1797995; AID1865885; AID1865893; AID1866708; AID240480; AID240481; AID241231; AID241719; AID241899; AID242068; AID242722; AID248083; AID248196; AID256998; AID264999; AID265001; AID265003; AID288628; AID379739; AID471238; AID471239; AID471240; AID501521; AID501525; AID625258; AID68750; AID69240; AID69868; AID70008; AID70198; AID70199; AID70317; AID70320; AID70330; AID70334; AID82214
Estrogen receptorHomo sapiens (human)Ki0.00070.00000.42297.9070AID1272983; AID1797926; AID254436; AID387083; AID625258; AID669588; AID669596; AID70345; AID70347
Estrogen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00320.00074.152114.1600AID69383; AID70013; AID70672
Tyrosine-protein kinase FynHomo sapiens (human)IC50 (µMol)3.66600.00021.67898.6800AID625185
Progesterone receptorHomo sapiens (human)IC50 (µMol)0.10000.00000.580710.0000AID1865894
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.28200.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki0.28000.00322.28879.3160AID625207
Cytochrome P450 3A4Homo sapiens (human)Ki9.90000.00011.41629.9000AID589149
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)1.66400.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.62400.00010.807410.0000AID625201
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)2.00000.00002.800510.0000AID625248
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)1.17400.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki0.39100.00000.651810.0000AID625253
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)3.69800.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki1.68800.00020.725710.0000AID625202
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)0.73800.00001.47257.8980AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.10700.00030.483410.0000AID625203
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)200.00000.00002.37899.7700AID1872410
Substance-K receptorHomo sapiens (human)IC50 (µMol)3.98900.00013.12109.5530AID625227
Substance-K receptorHomo sapiens (human)Ki1.33000.00011.92429.7930AID625227
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)3.86400.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki1.93200.00010.836310.0000AID625252
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)0.40000.00000.933210.0000AID625193
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.28200.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.28000.00031.465610.0000AID625207
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.97300.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.47800.00000.360910.0000AID625200
CruzipainTrypanosoma cruziIC50 (µMol)73.66670.00022.04508.0000AID444614; AID484274; AID484275
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)200.00000.00001.89149.5700AID1872411
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)1.45000.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.41400.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)1.17800.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.61700.00010.954910.0000AID625218
Adenosine receptor A2aHomo sapiens (human)IC50 (µMol)2.11100.00071.559410.0000AID625195
Adenosine receptor A2aHomo sapiens (human)Ki1.18500.00001.06099.7920AID625195
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)3.57600.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki1.90000.00000.70488.1930AID625222
C-8 sterol isomeraseSaccharomyces cerevisiae S288CKi0.06600.00000.90487.1500AID239296
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)1.17600.00010.813310.0000AID625163
Mu-type opioid receptorHomo sapiens (human)Ki0.47700.00000.419710.0000AID625163
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)1.56500.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.53100.00000.602010.0000AID625254
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)6.64400.00020.75218.0140AID625161
Delta-type opioid receptorHomo sapiens (human)Ki2.34200.00000.59789.9300AID625161
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)1.60200.00001.201110.0000AID625162
Kappa-type opioid receptorHomo sapiens (human)Ki0.64100.00000.362410.0000AID625162
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.35500.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.14750.00030.769310.0000AID537763; AID625217
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.75000.00020.522910.0000AID691260
Phospholipase D1 Rattus norvegicus (Norway rat)IC50 (µMol)20.00000.01100.34381.0000AID498481
Aldehyde oxidase 1Oryctolagus cuniculus (rabbit)IC50 (µMol)0.00800.00804.002710.0000AID1082235
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)1.86900.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki1.48500.00021.11158.0280AID625256
Aldehyde oxidaseHomo sapiens (human)IC50 (µMol)0.00550.00230.63203.3000AID1082235; AID547838
Aldehyde oxidaseHomo sapiens (human)Ki0.00090.00090.46072.3000AID1807417; AID1807418; AID1807419; AID547838
Platelet-activating factor acetylhydrolaseHomo sapiens (human)IC50 (µMol)0.00030.00000.38373.9000AID103888; AID103918
Phospholipase D1Homo sapiens (human)IC50 (µMol)7.68750.00101.06568.5000AID1799395; AID1799396; AID1799399; AID1801138; AID498477; AID498484; AID498485
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)Ki0.00100.00040.54906.7000AID239597
Aldehyde oxidase 1Macaca fascicularis (crab-eating macaque)IC50 (µMol)0.50000.11001.40333.6000AID547843
Estrogen receptor betaRattus norvegicus (Norway rat)IC50 (µMol)0.15840.00124.765214.1600AID69383; AID70177; AID70673
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)0.30510.00010.529432.7000AID102598; AID102601; AID103888; AID103918; AID1797853; AID1797989; AID1797992; AID1797995; AID1797996; AID1865886; AID1866709; AID240478; AID240479; AID241201; AID241684; AID241865; AID242043; AID242498; AID242704; AID248083; AID248196; AID256999; AID265000; AID265001; AID265003; AID288629; AID471237; AID501522; AID501527; AID68750; AID69240; AID70028; AID70029; AID70176; AID70513; AID70514; AID70518; AID70644; AID70650; AID82214
Estrogen receptor betaHomo sapiens (human)Ki0.00650.00000.12512.8760AID1272984; AID1797926; AID254433; AID387084; AID669589; AID70656; AID70658
Bile acid receptorHomo sapiens (human)IC50 (µMol)11.56000.01834.560310.0000AID755454
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.68100.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.16200.00000.490110.0000AID239347; AID625223
Aldehyde oxidase 1 Rattus norvegicus (Norway rat)IC50 (µMol)1.10000.19001.90606.4000AID547840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)11.71000.00203.519610.0000AID755445
Complement C5Homo sapiens (human)Kd0.71000.57000.62500.7100AID1601161
Estrogen receptorHomo sapiens (human)EC50 (µMol)0.01490.00000.53054.4000AID1594509; AID405515; AID70191
Phospholipase D1Homo sapiens (human)EC50 (µMol)9.25000.00101.23098.5000AID1799397; AID1799398
Estrogen receptor betaHomo sapiens (human)EC50 (µMol)0.26000.00000.47954.8900AID70507
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)Ka0.00020.00020.00020.0003AID1865885
Estrogen receptorHomo sapiens (human)Relative binding affinity0.01800.01800.01800.0180AID255402
Aldehyde oxidaseHomo sapiens (human)Kii0.00700.00700.65351.3000AID1807415
Estrogen receptor betaHomo sapiens (human)Ka0.04120.00200.02160.0412AID1865886
Estrogen receptor betaHomo sapiens (human)Relative binding affinity0.00400.00400.00400.0040AID255401
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (784)

Processvia Protein(s)Taxonomy
phosphatidic acid biosynthetic processPhospholipase D2Homo sapiens (human)
cytoskeleton organizationPhospholipase D2Homo sapiens (human)
small GTPase-mediated signal transductionPhospholipase D2Homo sapiens (human)
synaptic vesicle recyclingPhospholipase D2Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisPhospholipase D2Homo sapiens (human)
phospholipid catabolic processPhospholipase D2Homo sapiens (human)
regulation of vesicle-mediated transportPhospholipase D2Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chemotaxisComplement C5Homo sapiens (human)
inflammatory responseComplement C5Homo sapiens (human)
complement activation, alternative pathwayComplement C5Homo sapiens (human)
complement activation, classical pathwayComplement C5Homo sapiens (human)
cell surface receptor signaling pathwayComplement C5Homo sapiens (human)
G protein-coupled receptor signaling pathwayComplement C5Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionComplement C5Homo sapiens (human)
negative regulation of macrophage chemotaxisComplement C5Homo sapiens (human)
killing of cells of another organismComplement C5Homo sapiens (human)
positive regulation of chemokine productionComplement C5Homo sapiens (human)
cell chemotaxisComplement C5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
muscle contractionSubstance-K receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-K receptorHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionSubstance-K receptorHomo sapiens (human)
intestine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionSubstance-K receptorHomo sapiens (human)
operant conditioningSubstance-K receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-K receptorHomo sapiens (human)
positive regulation of monoatomic ion transportSubstance-K receptorHomo sapiens (human)
positive regulation of smooth muscle contractionSubstance-K receptorHomo sapiens (human)
response to electrical stimulusSubstance-K receptorHomo sapiens (human)
prolactin secretionSubstance-K receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-K receptorHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
lipid metabolic processAldehyde oxidaseHomo sapiens (human)
xenobiotic metabolic processAldehyde oxidaseHomo sapiens (human)
peptide hormone processingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particle remodelingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
lipid oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
plasma lipoprotein particle oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phosphatidylcholine catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor metabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of inflammatory responsePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of monocyte chemotaxisPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phosphatidic acid biosynthetic processPhospholipase D1Homo sapiens (human)
chemotaxisPhospholipase D1Homo sapiens (human)
small GTPase-mediated signal transductionPhospholipase D1Homo sapiens (human)
Ras protein signal transductionPhospholipase D1Homo sapiens (human)
cellular response to nutrientPhospholipase D1Homo sapiens (human)
regulation of microvillus assemblyPhospholipase D1Homo sapiens (human)
positive regulation of translationPhospholipase D1Homo sapiens (human)
regulation of synaptic vesicle cyclePhospholipase D1Homo sapiens (human)
phospholipid catabolic processPhospholipase D1Homo sapiens (human)
regulation of vesicle-mediated transportPhospholipase D1Homo sapiens (human)
cholesterol biosynthetic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol metabolic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
hemopoiesis3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via desmosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via lathosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
ossification involved in bone maturation3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (235)

Processvia Protein(s)Taxonomy
phospholipase D activityPhospholipase D2Homo sapiens (human)
protein bindingPhospholipase D2Homo sapiens (human)
phosphatidylinositol bindingPhospholipase D2Homo sapiens (human)
N-acylphosphatidylethanolamine-specific phospholipase D activityPhospholipase D2Homo sapiens (human)
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
endopeptidase inhibitor activityComplement C5Homo sapiens (human)
signaling receptor bindingComplement C5Homo sapiens (human)
protein bindingComplement C5Homo sapiens (human)
chemokine activityComplement C5Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
tachykinin receptor activitySubstance-K receptorHomo sapiens (human)
protein bindingSubstance-K receptorHomo sapiens (human)
substance K receptor activitySubstance-K receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
aldehyde oxidase activityAldehyde oxidaseHomo sapiens (human)
iron ion bindingAldehyde oxidaseHomo sapiens (human)
identical protein bindingAldehyde oxidaseHomo sapiens (human)
protein homodimerization activityAldehyde oxidaseHomo sapiens (human)
molybdopterin cofactor bindingAldehyde oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingAldehyde oxidaseHomo sapiens (human)
NAD bindingAldehyde oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingAldehyde oxidaseHomo sapiens (human)
FAD bindingAldehyde oxidaseHomo sapiens (human)
1-alkyl-2-acetylglycerophosphocholine esterase activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phospholipid bindingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
hydrolase activity, acting on ester bondsPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
calcium-independent phospholipase A2 activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phospholipase D activityPhospholipase D1Homo sapiens (human)
protein bindingPhospholipase D1Homo sapiens (human)
phosphatidylinositol bindingPhospholipase D1Homo sapiens (human)
N-acylphosphatidylethanolamine-specific phospholipase D activityPhospholipase D1Homo sapiens (human)
C-8 sterol isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
steroid delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
identical protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholestenol delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (140)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membranePhospholipase D2Homo sapiens (human)
plasma membranePhospholipase D2Homo sapiens (human)
presynapsePhospholipase D2Homo sapiens (human)
intracellular membrane-bounded organellePhospholipase D2Homo sapiens (human)
plasma membrane regionPhospholipase D2Homo sapiens (human)
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
extracellular regionComplement C5Homo sapiens (human)
extracellular spaceComplement C5Homo sapiens (human)
extracellular exosomeComplement C5Homo sapiens (human)
membrane attack complexComplement C5Homo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
sperm flagellumSubstance-K receptorHomo sapiens (human)
sperm headSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
cytosolAldehyde oxidaseHomo sapiens (human)
extracellular exosomeAldehyde oxidaseHomo sapiens (human)
extracellular regionPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
high-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
cholinergic synapsePhospholipase D1Homo sapiens (human)
Golgi membranePhospholipase D1Homo sapiens (human)
lysosomal membranePhospholipase D1Homo sapiens (human)
endosomePhospholipase D1Homo sapiens (human)
endoplasmic reticulum membranePhospholipase D1Homo sapiens (human)
Golgi apparatusPhospholipase D1Homo sapiens (human)
plasma membranePhospholipase D1Homo sapiens (human)
membranePhospholipase D1Homo sapiens (human)
apical plasma membranePhospholipase D1Homo sapiens (human)
endocytic vesiclePhospholipase D1Homo sapiens (human)
late endosome membranePhospholipase D1Homo sapiens (human)
specific granule membranePhospholipase D1Homo sapiens (human)
perinuclear region of cytoplasmPhospholipase D1Homo sapiens (human)
tertiary granule membranePhospholipase D1Homo sapiens (human)
intracellular membrane-bounded organellePhospholipase D1Homo sapiens (human)
plasma membrane regionPhospholipase D1Homo sapiens (human)
nuclear envelope3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cytoplasmic vesicle3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nuclear membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (690)

Assay IDTitleYearJournalArticle
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID471237Inhibition of fluormone ES2 binding to estrogen receptor beta after 1 hr by fluorescence polarization assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID1865914Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at G2/M phase at 0.1 nM after 24 hrs
AID70334In vitro inhibition of transcriptional activation induced by 1 nM 17-beta estradiol in T47D cells expressing estrogen receptor alpha2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.
AID1865926Oral bioavailability in rat at 5 mg/kg
AID1530770Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
AID189007Percent protection of bone mineral density in the distal femur of OVX rat at a dose of 10 mg/kg/day1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID235514Selectivity was determined as ratio of IC50 against human ER alpha to that of human ER beta2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID498478Inhibition of GFP-tagged human PLD2 expressed in human HEK293 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID590259Intrinsic clearance in rat liver microsomes in presence of NADPH2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID68919Displacement of [3H]17-beta-estradiol from estrogen receptor of MCF-7 cell lysate as relative binding affinity1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Synthesis and biological activity of trans-2,3-dihydroraloxifene.
AID1220799Drug metabolism in gallbladder-cannulated mouse assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID187054The compound was tested for uterotropic activity in immature rats(Dosage 1 ug)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
AID1693903Effect on cell cycle distribution in human MCF7 cells assessed as accumulation of cells at S phase at IC50 incubated for 72 hrs by PI staining based flow cytometry analysis2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1272977Binding affinity to synthetic ceramic hydroxyapatite type 1 assessed as reduction in bound compound level at 50 uM after 16 hrs by NMR spectroscopic analysis relative to alendronate2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID1220785Fraction unbound in rat plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID590256Intrinsic clearance in mouse liver microsomes in presence of UGT2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID256999Inhibition of binding to recombinant human ERbeta by scintillation proximity assay2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1601166Induction of human recombinant C5a unfolding by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID669589Displacement of [3H]estradiol from ERbeta after 4 hrs by scintillation counting2012ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3
Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs.
AID70672Binding to Estrogen receptor- alpha (ER alpha) receptor2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.
AID1283267Cytotoxicity against human SLOS fibroblasts at 5 uM after 5 days by Cell Titer assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID239597Affinity for human EMP expressed in ERG2 deficient strain of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine as radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID1865920Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor burden level at 5 mg/kg, po
AID1220798Half life in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1167568Acute toxicity in po dosed rat2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1220236Oral clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1202408Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as increase in trabecula thickness at 5 mg/kg/day, po administered six times a week for 3 months by toluidine blue staining-based light microscopic analysis relativ2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID186919The compound was tested for anti-uterotrophic activity in immature rats(Dosage 1 ug)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
AID252194Uterine wet weight in ovariectomized mice after 4 weeks of subcutaneous administration at 4 umol/kg (n=5)2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Benzothieno[3,2-b]indole derivatives as potent selective estrogen receptor modulators.
AID547843Inhibition of monkey aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID514395Cytostatic activity against human MCF7 cells at 5 uM after 3 days by microtiter assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
AID1659705Anti-osteoporosis activity in ovariectomized BALB/c mouse assessed as reduction in trabecular spacing in femur bone at 1 mg/kg, po via gavage administered for 1 month by microCT imaging analysis2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents.
AID1075149Inhibition of LIFR/GP130 interaction in human PANC-1 cells assessed as inhibition of LIF-induced STAT3 phosphorylation at Y705 at 25 uM after 24 hrs by Western blot analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
AID1572967Induction of ERalpha degradation in human MCF7 cells assessed as effect on ER protein/GADPH ratio at 100 nM after 4 hrs by Western blot analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
AID1053266Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF812972013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID247969In vitro antagonistic activity against MCF-7 cells was tested using proliferation assay2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains.
AID484276Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID55209Inhibition of Calmodulin activation of cyclic nucleotide phosphodiesterase1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanone.
AID405515Activity against estrogen receptor alpha2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Recent developments in fragment-based drug discovery.
AID102601Inhibition of estradiol-stimulated MCF-7 breast adenocarcinoma cell proliferation2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs).
AID1693883Therapeutic index, ratio of CC50 for inhibition of colony formation in human HSF cells to IC50 for inhibition of colony formation in ER and PR-positive human MCF7 cells2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1220258Renal clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1202364Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as alanine transaminase level at 5 mg/kg/day, po administered six times a week for 3 months (Rvb = 43.73 +/- 36.21 U/L)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1659702Anti-osteoporosis activity in ovariectomized BALB/c mouse assessed as increase in femur bone volume density at 1 mg/kg, po via gavage administered for 1 month by microCT imaging analysis2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1779059Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay2021European journal of medicinal chemistry, Oct-05, Volume: 221Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
AID70513Displacement of [3H]17-beta-estradiol from full length human estrogen receptor beta2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Estrogen receptor ligands. Part 4: The SAR of the syn-dihydrobenzoxathiin SERAMs.
AID1184074Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID590253Intrinsic clearance in mouse gut microsomes in presence of NADPH2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID236579Steady state volume of distribution in rat after administration of 1 mg/kg (iv) and 5 mg/kg (po)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID1865927Oral bioavailability in rat at 50 mg/kg
AID69055Displacement of [3H]17-beta-estradiol from estrogen receptor of MCF-7 cell lysates relative to 17-beta-estradiol1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Novel nonsteroidal selective estrogen receptor modulators. Carbon and heteroatom replacement of oxygen in the ethoxypiperidine region of raloxifene.
AID1598625Toxicity in ovariectomized-induced C57BL/6 mouse model of osteoporosis assessed as effect on body weight at 1 mg/kg, sc administered 6 days per week for 70 days measured post last dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Antisulfatase, Osteogenic, and Anticancer Activities of Steroid Sulfatase Inhibitor EO-33 in Mice.
AID241899Inhibition of bindign to recombinant human estrogen receptor alpha2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.
AID70196Agonist effect on transcriptional activation in T47D cells expressing estrogen receptor alpha; Inactive at 10e-4 M2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.
AID590266Intrinsic clearance in human gut microsomes in presence of UGT2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1693896Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at IC50 incubated for 72 hrs by Annexin V/FITC and PI staining based flow cytometry analysis (Rvb = 0.1 %)2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID498482Inhibition of human PLD2 assessed as release of methyl-[3H]choline from choline-methyl-[3H]dipalmitoylphosphatidylcholine after 30 mins by exogenous substrate assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1202410Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as increase in trabecula connectivity at 5 mg/kg/day, po administered six times a week for 3 months by toluidine blue staining-based light microscopic analysis rela2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1865896Antagonist activity at ERalpha in human MCF7 cells assessed as inhibition of p-Raf-1 activation at 0.1 to 1 nM measured after 24 hrs by Western blot analysis
AID590273Bioavailability in mouse2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1167558Cytotoxicity against human MDA-MB-435S cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID1865921Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor burden level at 50 mg/kg, po
AID69062Relative binding affinity of Estrogen receptor measured by using [3H]17-beta-estradiol1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID1807419Uncompetitive type inhibition of human AOX assessed as inhibition constant using nicotine-1(S)-iminium ion as substrate incubated for 2 mins by HPLC-MS analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case.
AID1163064Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID70008In vitro inhibition of [3H]17-beta-estradiol binding to human estrogen receptor alpha2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens.
AID244483Uterine weight assay of compound was determined in vivo against estrogen receptor alpha2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
AID614558Antiosteoporotic activity in Sprague-Dawley rat [45Ca] pre-labeled bone assessed as inhibition of PTH-induced bone resorption after 21 days2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents.
AID184853Minimally effective dose(MED) (mg/kg body weight) at which a statistically significant (p<= 0.05) increase in uterine weight/body weight was observed1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID444614Inhibition of Trypanosoma cruzi cruzain by quantitative high throughput screening2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease.
AID186916The compound was tested for anti-uterotrophic activity in immature rats(Dosage 10 microg)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
AID658143Displacement of [3H]-estradiol from estrogen receptor2012European journal of medicinal chemistry, May, Volume: 51Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.
AID1082237Inhibition of xanthine oxidase2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID102611In vitro antagonist effect on estrogen receptor alpha transcriptional activation in MCF-7 cells against 10 pM 17-beta-estradiol2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens.
AID1220800Drug metabolism in bile duct-cannulated monkey assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID484275Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in presence of 0.01% Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID67813Stimulation of alkaline phosphatase activity in Ishikawa human endometrial adenocarcinoma cells2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Synthesis and biological evaluation of novel thio-substituted chromanes as high-affinity partial agonists for the estrogen receptor.
AID16238Bioavailability was determined; extremely poor2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
AID239296Affinity for ERG2 of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1220239Unbound intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID471277Decrease in bone resorption in ovariectomized rat assessed as decrease in urine deoxypyridinoline level at 1 mg/kg, po administered daily measured after 6 weeks2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID70199Binding affinity against human estrogen receptor alpha in competitive binding assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID70347Binding affinity for estrogen receptor alpha2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs).
AID167570Inhibition of bone resorption in Rabbit osteoclast cells by Bone-pit assay2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.
AID1202341Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as white blood cells at 5 mg/kg/day, po administered six times a week for 3 months (Rvb = 6.28 +/- 2.78 x 10'9/L)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID70177Binding affinity foor Rat Estrogen receptor-beta2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
AID1202360Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as aspartate transaminase level at 5 mg/kg/day, po administered six times a week for 3 months (Rvb = 177.55 +/- 116.98 U/L)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID444613Inhibition of Beta-lactamase AmpC by quantitative high throughput screening2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease.
AID1202396Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as trabecula formation surface at 5 mg/kg/day, po administered six times a week for 3 months by fluorescence assay (Rvb = 7.82 +/- 2.46%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1167559Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID204322Effect on spine fractures in postmenopausal women with osteoporosis2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
AID1601165Binding affinity to human C5a assessed as change in enthalpy at 80 uM by isothermal titration calorimetry2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID70650In vitro binding affinity for estrogen receptor beta2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
A novel estrogen receptor ligand template.
AID1601156Binding affinity to recombinant human C5a assessed as conformational change =< 1 uM at 4 degC incubated for 1 hr by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID484274Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in absence of Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1167567Antitumor activity against mouse S180 cells allografted in ICR mouse assessed as tumor growth inhibition at 15 mg/kg, ip qd administered 24 hrs post tumor implantation for 9 days measured after 9 days relative to control2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID1693892Induction of ROS accumulation in human MCF7 cells at IC50 incubated for 72 hrs by DCFH-DA dye based fluorometric analysis relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1872411Inhibition of MAO-B (unknown origin)2022European journal of medicinal chemistry, Mar-05, Volume: 231Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID1693886Induction of mitochondrial membrane damage in human MCF7 cells assessed as reduction in mitochondrial membrane potential at 100 uM incubated for 1 hr by TMRE dye based fluorometric analysis relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1210793Ratio of Ki for uncompetitive inhibition of human liver cytosolic aldehyde oxidase to Ki for competitive inhibition of human liver cytosolic aldehyde oxidase2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID1283247Inhibition of delta 8-7 isomerase in mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1865885Antagonist activity at ERalpha (unknown origin)
AID1215398Effect on CYP3A4 (unknown origin) apoprotein formation at 10 uM pre-incubated for 3 mins by mass spectrometry analysis in presence of 1 mM NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID1283268Inhibition of delta 8-7 isomerase in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID184865Minimum effective dose at which significant increase in uterine weight/body weight in rat was determined (in vivo)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID590263Intrinsic clearance in dog liver microsomes in presence of NADPH2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1167564Antitumor activity against mouse 4T1 cells allografted in BALB/c mouse assessed as tumor growth inhibition at 1.8 mg/kg, ip administered 24 hrs post tumor implantation on even days of total 9 doses for 18 days relative to control2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1075152Binding affinity to GP130 in human RH30 cells assessed as protection against pronase-induced cleavage at 100 to 1000 uM preincubated for 1 hr followed by pronase induction measured after 30 mins by DARTS assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
AID187052The compound was tested for uterotropic activity in immature rats(Dosage 100 ug)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
AID265002Agonist activity at estrogen receptor in Ishikawa cells at 10 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID514397Cytostatic activity against human MCF7 cells at 10 uM after 3 days by microtiter assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
AID242960Selectivity ratio for ER beta to ER alpha receptor2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.
AID88460Effect on bone density of totalhip was determined in postmenopausal women2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
AID1601167Induction of human recombinant C5a destabilization assessed as protein structure helicity up to 10 uM by circular dichroism analysis (Rvb = 71%)2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1676109Antagonist activity at ER-alpha in human MCF-7:WS8 cells transfected with an estrogen response element assessed as suppression of estrogen-induced response incubated for 18 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID70191Inhibition of [3H]17-beta-estradiol binding to human recombinant Estrogen receptor alpha.2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID243059Ratio of inhibitory activity against human estrogen receptors 2 and 12005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
AID288628Displacement of [3H]estradiol from human recombinant ERalpha2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
AID184852Minimally effective dose(MED) (mg/kg body weight) at which a significant increase in EPO activity was observed in rats1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID1220786Fraction unbound in monkey plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1752634Inhibition of ERalpha (unknown origin) at 1 uM by fluorescence polarization assay relative to control2021Bioorganic & medicinal chemistry, 10-01, Volume: 47Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities.
AID1276573Antiproliferative activity against tamoxifen resistant human MCF7:5C cells assessed as inhibition of cell growth at 1 nM after 9 days by MTS assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
AID1558988Antiproliferative activity against human MCF7:5C cells assessed as reduction in cell viability incubated for 7 days by Hoechst 33258 dye based assay relative to control2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
AID243114IC50 ratio for binding to recombinant human estrogen receptors alpha and beta2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.
AID590257Intrinsic clearance in rat gut microsomes in presence of NADPH2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1220793Ratio of drug level in blood to plasma in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID214256Ability to inhibit release of interleukin-6 from U2OS cell lines transfected with estrogen receptor alpha2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
AID70345Ability to displace [3H]17-beta-estradiol from Estrogen receptor alpha by scintillation proximity assay.2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
2-Amino-4,6-diarylpyridines as novel ligands for the estrogen receptor.
AID236026Oral bioavailability in rat (dose 5 mg/kg)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID471239Antagonist activity at estrogen receptor in human Ishikawa cells assessed as 17-beta-estradiol-induced alkaline phosphatase activity after 3 days by chemiluminescence assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID501527Antagonist activity at human ERbeta E305A mutant expressed in HEK293T cells co-expressing ERE assessed as inhibition of ES8-induced transactivation by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID1312622Antiproliferative activity against human PC3 cells2016European journal of medicinal chemistry, Aug-25, Volume: 119Recent developments of C-4 substituted coumarin derivatives as anticancer agents.
AID1395071Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
AID590272Clearance in human2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1283273Decrease in cholesterol levels in human SLOS fibroblasts at 10 nM after 5 days by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1693885Induction of mitochondrial membrane damage in human MCF7 cells assessed as reduction in mitochondrial membrane potential at 50 uM incubated for 1 hr by TMRE dye based fluorometric analysis relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1693901Downregulation of ERalpha expression in human MCF7 cells at IC50 incubated for 72 hrs by Western blot assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID590274Bioavailability in rat2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID186917The compound was tested for anti-uterotrophic activity in immature rats(Dosage 1000 ug)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1659706Anti-osteoporosis activity in ovariectomized BALB/c mouse assessed as reduction in trabecular pattern factor in femur bone at 1 mg/kg, po via gavage administered for 1 month by microCT imaging analysis2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents.
AID102518Effect on bone density in the lumber spine was determined in postmenopausal women2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
AID1865893Antagonist activity at ERalpha in human MCF7 cells assessed as downregulation of ERalpha
AID1865919Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor latency time at 50 mg/kg, po
AID669590Selectivity ratio of Ki for ERbeta to Ki for ERalpha2012ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3
Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs.
AID471225Osteogenic effect on human MADS cells assessed as extracellular matrix calcification at 10 uM after 13 days by using alizarin red S dye2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives.
AID1210792Uncompetitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as enzyme-substrate complex by Lineweaver-Burk plot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID70198Displacement of [3H]17-beta-estradiol from full length human estrogen receptor alpha2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Estrogen receptor ligands. Part 4: The SAR of the syn-dihydrobenzoxathiin SERAMs.
AID471243Uterotropic activity in rat assessed as inhibition of estrone-stimulated uterine weight at 1 mg/kg, po QD after 3 days2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID1779057Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay2021European journal of medicinal chemistry, Oct-05, Volume: 221Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
AID1865922Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor volume at 5 mg/kg, po
AID1220784Fraction unbound in mouse plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1693888Induction of mitochondrial membrane damage in human MCF7 cells assessed as reduction in mitochondrial membrane potential at IC50 incubated for 72 hrs by TMRE dye based fluorometric analysis relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1075146Cytotoxicity against ER-negative human SUM159 cells assessed as cell viability after 72 hrs by MTT assay in presence of IL-62014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
AID501526Selectivity ratio of IC50 for human wild type ERalpha to IC50 for human ERalpha E353A mutant2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID1779060Displacement of fluorescent estradiol from recombinant ERalpha (unknown origin) at 1 uM measured after 2 hrs by fluorescence polarization assay2021European journal of medicinal chemistry, Oct-05, Volume: 221Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
AID187053The compound was tested for uterotropic activity in immature rats(Dosage 10 ug)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
AID590261Intrinsic clearance in dog gut microsomes in presence of NADPH2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1866711Selectivity index, ratio of IC50 for human recombinant ERbeta to human recombinant ERalpha2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.
AID70033Percent maximal inhibition of 1 nM 17-beta-estradiol induced transcriptional activation in T47D cells expressing estrogen receptor beta2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.
AID1659703Anti-osteoporosis activity in ovariectomized BALB/c mouse assessed as increase in trabecular number in femur bone at 1 mg/kg, po via gavage administered for 1 month by microCT imaging analysis2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents.
AID1202349Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as neutrophilic granulocytes level at 5 mg/kg/day, po administered six times a week for 3 months (Rvb = 31.95 +/- 8.33%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1082239Inhibition of Agaricus bisporus (mushroom) tyrosinase2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID705586Inhibition of CYP3A4 in human liver microsomes2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1163063Antiproliferative activity against human ER-positive Ishikawa cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID184047In vivo estrogenic activity in immature rat uterine weight assay at 0.6 mg/kg subcutaneous dose2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID590255Intrinsic clearance in mouse liver microsomes in presence of NADPH2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID232214Selectivity as ratio of IC50 for ER alpha to that of ER beta2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.
AID1317220Antiestrogenic activity at ERalpha in estrogen-sensitive human T47D cells assessed as blockage of E2 stimulated cell proliferation at 0.01 to 1 uM after 7 days in presence of E2 by MTS assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Discovery of a sulfamate-based steroid sulfatase inhibitor with intrinsic selective estrogen receptor modulator properties.
AID590254Intrinsic clearance in mouse gut microsomes in presence of UGT2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID471271Estrogenic activity in ovariectomized rat assessed as minor increase in uterine epithelial thickness at 1 mg/kg, po administered daily measured after 6 week by immunohistochemical analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID1601157Binding affinity to recombinant human C5a assessed as loss of super secondary structure at > 10 uM incubated for 1 hr at 4 degC by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID430531Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as average osteoid width at 5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID471240Antagonist activity at estrogen receptor in human MCF7 cells assessed as 17-beta-estradiol-induced cell proliferation after 24 hrs by [14C]thymidine incorporation assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID430524Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as osteo cortex mineralization rate at 5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID191704Uterotrophic effect as uterine weight gain in rats at 1 mg/kg/day oral dose for 4 days2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
4-(4-alkylpiperazin-1-yl)phenyl group: a novel class of basic side chains for selective estrogen receptor modulators.
AID1272982Binding affinity to hound collagen 1a1 (unknown origin) at 50 uM after 1 8 hrs by 1H NMR spectroscopic analysis2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID501536Agonist activity at human wild type ERbeta expressed in human HeLa cells co-expressing AP-1 assessed as transactivation activity by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID1693899Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at IC50 incubated for 72 hrs by Annexin V/FITC and PI staining based flow cytometry analysis (Rvb = 0.2 %)2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID250488Antagonistic activity in rat in vivo uterine weight assay after 1 mg/kg oral dose2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.
AID657937Relative binding affinity to estrogen receptor2012European journal of medicinal chemistry, May, Volume: 51Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.
AID1167563Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID430517Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as mineral apposition rate at 5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1872410Inhibition of MAO-A (unknown origin)2022European journal of medicinal chemistry, Mar-05, Volume: 231Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID1865886Antagonist activity at ERbeta (unknown origin)
AID1053260Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID244481Effect on mouse bone mineral density2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
AID590264Intrinsic clearance in dog liver microsomes in presence of UGT2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1312621Antiproliferative activity against human MDA-MB-231 cells2016European journal of medicinal chemistry, Aug-25, Volume: 119Recent developments of C-4 substituted coumarin derivatives as anticancer agents.
AID1220238Intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID547622Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID1865890Antiproliferative activity against human MDA-MB-231 cells
AID70320Binding affinity towards human recombinant Estrogen receptor alpha was determined2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
AID173691Percent decrease in serum cholesterol relative to OVX control at 0.1 mg/kg in rat was determined (in vivo)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID1272971Binding affinity to hound bone powder assessed as change in vibration bands at 20 to 50 uM after 1 hr by FTIR analysis2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID233594Selectivity as ratio of IC50 against ER beta receptor to IC50 against ER alpha receptor2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1865891Selectivity index, ratio IC50 for antiproliferative activity against human MDA-MB-231 cells over IC50 for antiproliferative activity against human MCF7 cells
AID102437Percent agonistic activity for estrogen-induced pS2 expression in MCF-7 cells; ND= not determined2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
A novel estrogen receptor ligand template.
AID257002In vivo antagonism of estradiol in rat uterine tissue after 1 mg/kg, po by uterine weight assay2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.
AID1865937Toxicity in female Wistar rat xenografted with methyl nitroso urea (MNU)-preinduced breast cancer assessed as appearance of less differentiated extra lobular ducts at 50 mg/kg, po
AID255401Binding affinity towards human estrogen receptor beta in a competitive binding assay using fluorescently labelled estradiol; relative to 4-hydroxytamoxifen2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
AID70013Binding affinity for Rat Estrogen receptor-alpha2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
AID1693877Selectivity index, ratio of IC50 for ER- negative human MDA-MB-231 cells to IC50 for ER and PR-positive human MCF7 cells2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1272984Binding affinity to ERbeta (unknown origin)2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID590258Intrinsic clearance in rat gut microsomes in presence of UGT2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID430496Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecular bone volume at 5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID70342Percent maximal inhibition of transcriptional activation stimulated by 1 nM 17 beta-estradiol in T47D cells expressing estrogen receptor alpha2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.
AID70330In vitro binding affinity for estrogen receptor alpha2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
A novel estrogen receptor ligand template.
AID1676127Antiviral activity against pseudotyped Marburgvirus-Musoke infected in human A549 cells assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID70644Binding affinity towards human recombinant Estrogen receptor beta was determined2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
AID1693898Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at IC50 incubated for 72 hrs by Annexin V/FITC and PI staining based flow cytometry analysis (Rvb = 14.4 +/- 0.4 %)2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID250426Bone mineral density of DFM:central in female ovariectomized rats at 1.5 mg/kg (for 6 weeks)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs.
AID547840Inhibition of rat aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID1865912Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at S phase at 1 nM after 24 hrs
AID244487Uterine weight assay of sham type raloxifene was determinedn in vivo against estrogen receptor alpha2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
AID241684Inhibition of [3H]17-beta-estradiol binding to human estrogen receptor beta2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Benzothieno[3,2-b]indole derivatives as potent selective estrogen receptor modulators.
AID1779058Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay2021European journal of medicinal chemistry, Oct-05, Volume: 221Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
AID1317232Agonist activity at ERalpha in human Saos2 cells assessed as increase in ALP activity using p-nitrophenyl phosphate as substrate at 0.1 nM after 3 days by colorimetric assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Discovery of a sulfamate-based steroid sulfatase inhibitor with intrinsic selective estrogen receptor modulator properties.
AID1739454Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as increase in trabecular bone volume at 5 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID1739455Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as increase in trabecular bone mineral density at 5 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID1659704Anti-osteoporosis activity in ovariectomized BALB/c mouse assessed as increase in trabecular thickness in femur bone at 1 mg/kg, po via gavage administered for 1 month by microCT imaging analysis2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents.
AID1693900Effect on cell cycle distribution in human MCF7 cells assessed as accumulation of cells at G1 phase at IC50 incubated for 72 hrs by PI staining based flow cytometry analysis2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID430503Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecula resorption surface at 5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1594511Agonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ER-alpha-mediated transcriptional activity at 10 uM by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1601155Binding affinity to recombinant human C5a assessed as conformational change at 1 to 100 uM incubated for 1 hr at 4degC by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID300326Effect on uterine wet weight in ovariectomized kunming mouse at 4 umol/kg, sc qd for 4 weeks2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Aza analogues of equol: novel ligands for estrogen receptor beta.
AID70518Binding affinity towards human estrogen receptor beta (ERbeta)2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1210791Competitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as free enzyme by Lineweaver-Burk plot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID1075148Inhibition of IFN-gamma receptor/GP130 interaction in human PANC-1 cells assessed as inhibition of IFN-gamma-induced STAT1 phosphorylation at Y701 at 25 uM preincubated for 30 mins followed by IFN-gamma induction measured after 24 hrs by Western blot anal2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
AID1865918Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor latency time at 5 mg/kg, po
AID1693889Induction of mitochondrial membrane damage in human MDA-MB-231 cells assessed as reduction in mitochondrial membrane potential at IC50 incubated for 72 hrs by TMRE dye based fluorometric analysis relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID590271Clearance in dog2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID755445Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID589149Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID82214In vivo inhibition of human ERalpha/ERbeta co-expressed in HEK 293 cells; 4/602004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1220801Drug metabolism in bile duct-cannulated dog assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID250410Agonistic activity in rat in vivo uterine weight assay at 1 mg/kg oral dose2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.
AID241231Inhibition of estrogen receptor alpha2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
AID244485Uterine weight assay of ovx type raloxifene was determined in vivo against estrogen receptor alpha2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
AID1530772Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
AID1866709Binding affinity to human recombinant ERbeta by competitive fluorometric binding assay2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.
AID501521Antagonist activity at human ERalpha E353A mutant expressed in HEK293T cells co-expressing ERE assessed as inhibition of ES8-induced transactivation by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID68750Displacement of [3H]estradiol from Estrogen receptor in MCF-7 cells1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanone.
AID102777Antagonist activity in MCF-7 breast tumor cell proliferation assay, based on pS2 gene expression at 10 nM2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.
AID1572966Induction of ERalpha degradation in human MCF7 cells assessed as effect on ER protein/GADPH ratio at 10 nM after 4 hrs by Western blot analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
AID236640Maximum plasma concentration of compound in rat after peroral administration of 5 mg/kg2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID379739Antagonist activity at human ERalpha expressed in african green monkey CV1 cells assessed as inhibition of estrogen like activity after 24 hrs by luciferase reporter gene assay2006Journal of natural products, Feb, Volume: 69, Issue:2
Bioactive compounds from Peperomia pellucida.
AID242704Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor beta; ERE assay2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID252870Percent antagonism of estradiol in rat uterine tissue at 1 mg/kg2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.
AID1693893Induction of ROS accumulation in human MDA-MB-231 cells at IC50 incubated for 72 hrs by DCFH-DA dye based fluorometric analysis relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID184864Minimum effective dose at which significant increase in uterine eosinophil peroxidase (EPO) activity in rat was determined (in vivo)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID1865908Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at G0/G1 phase at 0.1 nM after 24 hrs
AID288627Selectivity for human ERbeta over human ERbeta2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
AID1316141Drug metabolism in human liver S9 fraction assessed as 1-(2-(1-morpholinopropan-2-ylamino)benzo[d]thiazol-6-yl)-8-(pyridin-4-yl)-1H-imidazo[4,5-c][1,7]naphthyridin-4(5H)-one metabolite formation in presence of aldehyde oxidase inhibitor raloxifene2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.
AID1598620Estrogenic activity in ovariectomized-induced C57BL/6 mouse model of osteoporosis assessed as stimulation of uterus weight at 1 mg/kg, sc administered 6 days per week for 70 days measured post last dose by necropsy analysis2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Antisulfatase, Osteogenic, and Anticancer Activities of Steroid Sulfatase Inhibitor EO-33 in Mice.
AID1167557Cytotoxicity against mouse CCL8 cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID1220794Plasma clearance in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID183187Anti-estrogenic activity as percent inhibition/control in uterotrophic assay on co-administration with subcutaneous 17-beta-estradiol in rats; 96/82004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs.
AID178720Dose required to reduce serum cholesterol by 50% relative to ovariectomized (OVX) controls1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID1210794Protein binding in plasma (unknown origin)2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID1572958Antiproliferative activity against human MCF7 cells at 10 to 300 nM after 5 days by crystal violet staining based assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
AID102593Inhibition of estrogen-stimulated MCF-7 cell proliferation1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID70028Binding affinity for Human Estrogen receptor-beta2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
AID1558987Antiproliferative activity against human MCF7:5C cells assessed as reduction in cell viability incubated for 7 days by Hoechst 33258 dye based assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
AID1220260Oral bioavailability in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID498485Inhibition of human PLD1b2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID257003In vivo agonism of estradiol in rat uterine tissue after 1 mg/kg, po by uterine weight assay2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID471545Increase in vaginal secretion in ovariectomized rat at 1 mg/kg, po administered daily measured after 2 weeks by cytology analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID265003Inhibition of estrogen receptor in MCF7 cells2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID1184068Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1220792Ratio of drug level in blood to plasma in dog2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1301303Displacement of Fluormone ES2 from human recombinant full length untagged-ERalpha by fluorescence polarization competition binding assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID173698Percent decrease in serum cholesterol relative to OVX controls, at 0.01 mg/Kg compound dose1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID1865936Toxicity in female Wistar rat xenografted with methyl nitroso urea (MNU)-preinduced breast cancer assessed as appearance of less differentiated extra lobular ducts at 5 mg/kg, po
AID103888Antagonism of estrogen action in a mammary tumor cell line was assayed via inhibition of MCF-7 cell proliferation stimulated by 10 e-11 M 17-beta-estradiol (in vitro)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID501531Antagonist activity at human wild type ERalpha expressed in human HeLa cells co-expressing ERE assessed as inhibition of transactivation activity by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID501535Antagonist activity at human wild type ERbeta expressed in human HeLa cells co-expressing ERE assessed as inhibition of transactivation activity by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID755448Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation at 20 uM after 16 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID397672Growth inhibition of estrogen receptor deficient human MDA-MB-231 cells at 3.2 nM to 50 uM after 72 hrs by MTS assay2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor beta.
AID184113Minimum effective dose at which significant increase in uterine weight/body weight in rat was determined (in vivo); expressed as % increase relative to ovariectomized (OVX) controls1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID1865911Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at S phase at 0.1 nM after 24 hrs
AID1865923Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor volume at 50 mg/kg, po
AID1276579Cytotoxicity against human MCF7:WS8 cells at 0.1 to 1 uM after 3 days by MTT assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
AID1053262Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1272976Binding affinity to synthetic ceramic hydroxyapatite type 1 assessed as reduction in bound compound level at 50 uM after 1 hr by NMR spectroscopic analysis relative to alendronate2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID547838Inhibition of human aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID1220256Total clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID254433Antagonistic activity against estrogen receptor beta in presence of 0.1 nM estradiol2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
AID1865925Plasma protein binding in rat at 50 mg/kg, po
AID1202400Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as trabecula resorption surface at 5 mg/kg/day, po administered six times a week for 3 months by fluorescence assay (Rvb = 7.22 +/- 2.04%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID240480Binding potency for human ER alpha2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains.
AID102598In vitro inhibition of estrogen-stimulated MCF-7 cell proliferation1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Novel nonsteroidal selective estrogen receptor modulators. Carbon and heteroatom replacement of oxygen in the ethoxypiperidine region of raloxifene.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1220259Oral absorption in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID264999Binding affinity to ERalpha2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID471244Uterotropic activity in rat assessed as increase in uterine weight at 1 mg/kg, po QD after 3 days2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID1693874Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID244701Increased bone mineral density in ovariectomized Kun-Ming mice after subcutaneous administration at 4 umol/kg for 4 weeks (n=5)2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Benzothieno[3,2-b]indole derivatives as potent selective estrogen receptor modulators.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1283269Inhibition of DR24 in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1572961Induction of ERalpha degradation in human MCF7 cells assessed as effect on ER protein/GADPH ratio at 1 nM after 4 hrs by Western blot analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1272974Binding affinity to synthetic ceramic hydroxyapatite type 1 assessed as reduction in bound compound level at 50 uM after 1 hr by NMR spectroscopic analysis relative to control2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID397669Cytotoxicity against estradiol-stimulated human MCF7 cells expressing ERalpha and ERbeta at 25 uM after 6 days by MTS assay2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor beta.
AID1272980Binding affinity to hound bone powder assessed as reduction in bound compound level at 50 uM after 1 hr by NMR spectroscopic analysis relative to alendronate2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID1317226Agonist activity at ERalpha in estrogen-sensitive human T47D cells assessed as induction of cell proliferation at 0.01 to 5 uM after 7 days by MTS assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Discovery of a sulfamate-based steroid sulfatase inhibitor with intrinsic selective estrogen receptor modulator properties.
AID1215348Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
A refined cytochrome P540 ICâ‚…â‚€ shift assay for reliably identifying CYP3A time-dependent inhibitors.
AID179988In vivo prevention of bone loss in ovariectomised rats on oral administration1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
AID186921The compound was tested for uterotropic activity in immature rats(Dosage 1000 ug)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
AID547804Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID252866Percent agonism of estradiol in rat uterine tissue at 1 mg/kg2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.
AID1872409Inhibition of KDM1A (unknown origin)2022European journal of medicinal chemistry, Mar-05, Volume: 231Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID1317227Cytotoxicity against estrogen-sensitive human T47D cells assessed as reduction in cell proliferation at 5 uM after 7 days by MTS assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Discovery of a sulfamate-based steroid sulfatase inhibitor with intrinsic selective estrogen receptor modulator properties.
AID1220255Apparent permeability by PAMPA method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1676126Antiviral activity against pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1210790Uncompetitive inhibition of human liver cytosolic aldehyde oxidase using phthalazine as substrate assessed as enzyme-substrate complex by Lineweaver-Burk plot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID173699Percent decrease in serum cholesterol relative to OVX controls, at 0.1 mg/Kg compound dose1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID14012Oral bioavailability in cynomolgus monkey.1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
AID537763Displacement of [3H]LSD from human cloned 5HT2B receptor expressed in CHO cells by liquid scintillation counting2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
AID69383Inhibition of estradiol binding to estrogen receptor1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
AID1739453Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as narrowed gap between trabeculae at 5 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID70025Agonist effect on transcriptional activation of T47D cells expressing human estrogen receptor beta; Inactive at 10e-4 M2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.
AID288625Displacement of [3H]estradiol from human recombinant ERalpha relative to estradiol2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
AID1312620Antiproliferative activity against human MCF7 cells2016European journal of medicinal chemistry, Aug-25, Volume: 119Recent developments of C-4 substituted coumarin derivatives as anticancer agents.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID755454Antagonist activity at human GTS-tagged FXR after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID551635Antiestrogenic activity in ovariectomized Sprague-Dawley rat assessed as inhibition of 17beta estradiol-induced increase in uterine weight at 3 mg/kg, po qd for 3 days2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Synthetic analogs of daidzein, having more potent osteoblast stimulating effect.
AID1594506Binding affinity to GST-tagged human ER alpha ligand-binding domain by TR-FRET assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID247970In vitro antagonistic activity against MCF-7 cells was tested using proliferation assay2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.
AID234314Selectivity of IC50[ERbeta] / IC50[ERalpha]2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs.
AID186918The compound was tested for anti-uterotrophic activity in immature rats(Dosage 100 ug)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
AID590270Clearance in rat2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1558990Antiproliferative activity against human MCF7:WS8 cells assessed as reduction in cell viability incubated for 5 days by Hoechst 33258 dye based assay relative to control2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
AID551633Estrogenic activity in ovariectomized Sprague-Dawley rat assessed as effect on uterine weight at 3 mg/kg, po qd for 3 days (Rvb = 35.0 +/- 0.6)2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Synthetic analogs of daidzein, having more potent osteoblast stimulating effect.
AID242068Inhibition of [3H]estradiol binding to human estrogen receptor alpha expressed in HeLa cells2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID248196In vitro inhibition of estradiol-stimulated MCF-7 breast cancer cell proliferation2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.
AID590265Intrinsic clearance in human gut microsomes in presence of NADPH2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID236196Total clearance of compound in rat after administration of 1 mg/kg (iv) and 5 mg/kg (po)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID67812Percent stimulation of alkaline phosphatase activity in Ishikawa human endometrial adenocarcinoma cells relative to moxestrol2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Synthesis and biological evaluation of novel thio-substituted chromanes as high-affinity partial agonists for the estrogen receptor.
AID484389Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 20 uM by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1220788Fraction unbound in human plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID514396Cytostatic activity against human MDA-MB-231 cells after 3 days by microtiter assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
AID387083Displacement of [3H]estradiol from full length biotinylated human ERalpha by scintillation proximity assay2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Synthesis of 3-alkyl naphthalenes as novel estrogen receptor ligands.
AID501525Antagonist activity at human wild type ERalpha expressed in HEK293T cells co-expressing ERE assessed as inhibition of estradiol-induced transactivation by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID69868Binding affinity for Human Estrogen receptor-alpha2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
AID1572954Inhibition of cell growth in human MCF7 cells after 4 days by wst-8-based colorimetric analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
AID1220797Volume of distribution at steady state in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1807415Uncompetitive type inhibition of human AOX assessed as inhibitor dissociation constant by measuring intercept of the double reciprocal plot using phenanthridine as substrate by spectrophotometry based Lineweaver-Burk plot analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case.
AID1272983Binding affinity to ERalpha (unknown origin)2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID1202407Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as increase in trabecula number at 5 mg/kg/day, po administered six times a week for 3 months by toluidine blue staining-based light microscopic analysis relative t2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID70317Binding affinity towards human estrogen receptor alpha2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs.
AID1220245Activity of human UGT1A8 expressed in insect cells assessed as reduction in compound level after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1693876Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID250113Percent uterine growth in female ovariectomized rat at 1.5 mg/kg (for 6 weeks)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1220246Activity of human UGT1A10 expressed in insect cells assessed as reduction in compound level after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1283262Inhibition of DR24 in human SLOS fibroblasts assessed as decrease in 7-DHC levels at 10 nM after 5 days by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID240479Binding potency for human ER beta2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.
AID1693880Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1075150Inhibition of IL-6Ralpha/GP130 interaction in human PANC-1 cells assessed as inhibition of IL-6-induced STAT3 phosphorylation at Y705 preincubated for 30 mins followed by IL-6 induction measured after 24 hrs by Western blot analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
AID1220241Intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1530769Antiproliferative activity against HUVEC after 48 hrs by MTT assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
AID1202367Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as triglycerides level at 5 mg/kg/day, po administered six times a week for 3 months (Rvb = 1.13 +/- 0.69 mmol/L)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID256998Inhibition of binding to recombinant human ERalpha by scintillation proximity assay2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1220783Drug metabolism in human assessed as glucuronide concentration in bile and urine2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID288629Displacement of [3H]estradiol from human recombinant ERbeta2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
AID1594509Selective estrogen receptor down-regulator activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ERalpha degradation by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID70661Transcriptional activation in HeLa cells expressing human estrogen receptor beta; No data2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID1865889Antiproliferative activity against human MCF7 cells
AID242498Inhibition of human estrogen receptor 2 using tritiated estradiol incubated for 3 hr2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
AID471241Agonist activity at estrogen receptor in human Ishikawa cells assessed as 17-beta-estradiol-induced alkaline phosphatase activity at 10 uM after 3 days by chemiluminescence assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID1283275Inhibition of DR24 in mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1693902Upregulation of Akt expression in human MCF7 cells at IC50 incubated for 72 hrs by Western blot assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1594510Selective estrogen receptor down-regulator activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ERalpha degradation by luciferase reporter gene assay relative to untreated control2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1693895Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at IC50 incubated for 72 hrs by Annexin V/FITC and PI staining based flow cytometry analysis (Rvb = 9.4 +/- 0.4 %)2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID241719Inhibition of [3H]17-beta-estradiol binding to human estrogen receptor alpha2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Benzothieno[3,2-b]indole derivatives as potent selective estrogen receptor modulators.
AID547839Inhibition of mouse aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID1272973Binding affinity to hound bone powder at 50 uM after 1 to 8 hrs by 1H NMR spectroscopic analysis2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID498484Inhibition of human PLD1 assessed as release of methyl-[3H]choline from choline-methyl-[3H]dipalmitoylphosphatidylcholine after 30 mins by exogenous substrate assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1215349Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined CYP450 IC50 s2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
A refined cytochrome P540 ICâ‚…â‚€ shift assay for reliably identifying CYP3A time-dependent inhibitors.
AID70502Binding affinity against estrogen receptor alpha relative to E22004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID244484Bone mineral density of ovx type raloxifene was determined in vivo against estrogen receptor alpha2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
AID1865892Antiproliferative activity against human MRC5 cells
AID1220242Unbound intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1866710Binding affinity to human recombinant ERalpha by competitive fluorometric binding assay relative to 17beta-estradiol2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.
AID1676125Selectivity index, ratio of CC50 for human A549 cells to IC50 for antiviral activity against pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1693891Induction of ROS accumulation in human MCF7 cells at 50 to 100 uM incubated for 1 hr by DCFH-DA dye based fluorometric analysis relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID69240Displacement of [3H]17-beta-estradiol from Estrogen receptor of rabbit uterine tissue2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Synthesis and biological evaluation of novel thio-substituted chromanes as high-affinity partial agonists for the estrogen receptor.
AID658133Antiproliferative activity against human MCF7 cells2012European journal of medicinal chemistry, May, Volume: 51Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.
AID590276Bioavailability in human2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID300325Effect on bone mineral density in ovariectomized kunming mouse at 4 umol/kg, sc qd for 4 weeks2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Aza analogues of equol: novel ligands for estrogen receptor beta.
AID70514Binding affinity against human estrogen receptor beta (ER beta) in competitive binding assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID257000Selectivity for human ERbeta over ERalpha2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1220789Ratio of drug level in blood to plasma in mouse2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1572955Inhibition of cell growth in human MCF7 cells after 4 days by wst-8-based colorimetric analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
AID614559Antiosteoporotic activity in Sprague-Dawley rat [45Ca] pre-labeled bone assessed as inhibition of PTH-induced bone resorption after 21 days relative to control2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents.
AID70658Binding affinity for estrogen receptor beta2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs).
AID1163062Antiproliferative activity against human prostate, androgen receptor positive DU145 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1220795Plasma clearance in po dosed human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID590260Intrinsic clearance in rat liver microsomes in presence of UGT2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1693882Selectivity index, ratio of IC50 for inhibition of colony formation in ER-negative human MDA-MB-231 cells to IC50 for inhibition of colony formation in ER and PR-positive human MCF7 cells2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID471222Cytotoxicity against human ADSC at 10 uM after 3 days by MTT assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives.
AID1693887Induction of mitochondrial membrane damage in human MDA-MB-231 cells assessed as reduction in mitochondrial membrane potential at 100 uM incubated for 1 hr by TMRE dye based fluorometric analysis relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1276568Displacement of fluorescein labelled E2 from full length estrogen receptor alpha (unknown origin) after 2 hrs by fluorescence polarization assay relative to raloxifene2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
AID498481Inhibition of N-terminally truncated rat PLD1 assessed as release of methyl-[3H]choline from choline-methyl-[3H]dipalmitoylphosphatidylcholine after 30 mins by exogenous substrate assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID173693Percent decrease in serum cholesterol relative to OVX control at 1 mg/kg in rat1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID189006Percent protection of bone mineral density in the distal femur of OVX rat at a dose of 1 mg/kg/day1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID691260Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells after 1.5 hrs by liquid scintillation counting2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.
AID1215400Effect on recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as heme level LC/UV/MS analysis in presence of 1 mM NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
AID1865895Antiproliferative activity against human Ishikawa cells
AID102407Percent agonistic activity for estrogen-induced pS2 expression in MCF-7 cells compared to estradiol2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
A novel estrogen receptor ligand template.
AID70489Selectivity ratio for binding to estrogen receptor alpha compared to estrogen receptor beta2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
A novel estrogen receptor ligand template.
AID1865900Antagonist activity at ERalpha in human MCF7 cells assessed as effect on total levels of Raf-1 at 0.1 to 1 nM measured after 24 hrs by Western blot analysis
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID14017Oral bioavailability in rat1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
AID669588Displacement of [3H]estradiol from ERalpha after 4 hrs by scintillation counting2012ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3
Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs.
AID1220796Drug metabolism in bile duct-cannulated rat assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1693879Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1317230Agonist activity at ERalpha in human Saos2 cells assessed as induction of cell proliferation at 1 nM to 1 uM after 7 days by MTS assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Discovery of a sulfamate-based steroid sulfatase inhibitor with intrinsic selective estrogen receptor modulator properties.
AID1739451Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as increase in number of trabeculae at 5 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID1276567Agonist activity at estrogen receptor alpha in human MCF7:WS8 cells after 18 hrs by dual luciferase reporter assay relative to E22016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
AID1202409Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as increase in trabecula area at 5 mg/kg/day, po administered six times a week for 3 months by toluidine blue staining-based light microscopic analysis relative to 2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1082238Inhibition of Oryctolagus cuniculus (rabbit) AOX in liver cytosol2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID252869Percent antagonism of estradiol effects in rat uterine tissue at 1 mg/kg2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID239347Affinity for sigma receptor type 1 of guinea pig using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID1865901Antagonist activity at ERalpha in human MCF7 cells assessed as effect on total levels of ERK1/2 at 0.1 to 1 nM measured after 24 hrs by Western blot analysis
AID1865935Toxicity in female Wistar rat xenografted with methyl nitroso urea (MNU)-preinduced breast cancer assessed as reduction in breast epithelial density at 50 mg/kg, po
AID1601164Binding affinity to human C5a assessed as Potassium iodide-induced quenching by measuring Stern-Volmer quenching constant at 1 uM by fluorescence analysis (Rvb = 4.1/M)2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1075151Inhibition of IL-6Ralpha/GP130 interaction in ER-negative human SUM159 cells overexpressing IL-6 assessed as inhibition of constitutive STAT3 phosphorylation at Y705 at 15 to 50 uM after 24 hrs by Western blot analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
AID1807418Uncompetitive type inhibition of human AOX assessed as inhibition constant using vanillin as substrate by HPLC-MS analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case.
AID257001Antiproliferative activity against human breast cancer MCF7 cell line in presence of 0.003 nM estradiol2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.
AID1693897Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at IC50 incubated for 72 hrs by Annexin V/FITC and PI staining based flow cytometry analysis (Rvb = 87.8 +/- 0.4 %)2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID501522Antagonist activity at human wild type ERbeta expressed in HEK293T cells co-expressing ERE assessed as inhibition of estradiol-induced transactivation by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID103897Antiproliferative activity against MCF-7 cell line2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
AID1865924Plasma protein binding in rat at 5 mg/kg, po
AID70176In vitro inhibitory concentration against [3H]17-beta-estradiol binding to human estrogen receptor 22001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens.
AID1272975Binding affinity to synthetic ceramic hydroxyapatite type 1 assessed as reduction in bound compound level at 50 uM after 16 hrs by NMR spectroscopic analysis relative to control2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID1530771Stimulation of cell proliferation in human Ishikawa cells at 1 to 10 uM after 48 hrs by MTT assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
AID255402Binding affinity towards human estrogen receptor alpha in a competitive binding assay using fluorescently labelled estradiol; relative to 4-hydroxytamoxifen2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
AID70029In vitro inhibition of 1 nM 17-beta-estradiol induced transcriptional activation in T47D cells expressing estrogen receptor beta2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.
AID397670Cytotoxicity against estradiol-stimulated human MCF7 cells expressing ERalpha at 25 uM after 6 days by MTS assay2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor beta.
AID249854Percent agonistic activity towards uterus effects in ovariectomized mice after 4 weeks of 4 umol/kg subcutaneous administration (n=5)2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Benzothieno[3,2-b]indole derivatives as potent selective estrogen receptor modulators.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1163060Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1220237Unbound fraction during UGT-mediated glucuronidation in human intestinal microsomes2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1601163Binding affinity to human C5a assessed as loss of secondary structure by measuring red shift in absorption maxima at 10 to 100 uM by fluorescence analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1167560Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID240481Binding potency for human ER alpha2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.
AID1316140Drug metabolism in Sprague-Dawley rat liver S9 fraction assessed as 1-(2-(1-morpholinopropan-2-ylamino)benzo[d]thiazol-6-yl)-8-(pyridin-4-yl)-1H-imidazo[4,5-c][1,7]naphthyridin-4(5H)-one metabolite formation in presence of aldehyde oxidase inhibitor ralox2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1075144Cytotoxicity against human MIAPaCa2 cells assessed as cell viability2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
AID1220790Ratio of drug level in blood to plasma in rat2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID240478Binding potency for human ER beta2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains.
AID590268Intrinsic clearance in human liver microsomes in presence of UGT2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID250368Percent agonist activity against human breast adenocarcinoma (MCF-7) cell proliferation2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID1167562Cytotoxicity against mouse MG-22A cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID1272978Binding affinity to hound bone powder assessed as reduction in bound compound level at 50 uM after 1 hr by NMR spectroscopic analysis relative to control2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID1272979Binding affinity to hound bone powder assessed as reduction in bound compound level at 50 uM after 16 hrs by NMR spectroscopic analysis relative to control2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID189004Percent protection of bone mineral density in the distal femur of OVX rat at a dose of 0.01 mg/kg/day1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID254436Antagonistic activity against estrogen receptor alpha in presence of 0.1 nM estradiol2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
AID501532Transactivation of human wild type ERalpha expressed in human HeLa cells co-expressing AP-1 by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID1272972Binding affinity to hound bone beams assessed as energy to fracture at 2 uM by 4 point bending analysis relative to control2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID1202392Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as trabecular bone volume at 5 mg/kg/day, po administered six times a week for 3 months by fluorescence assay (Rvb = 33.09 +/- 5.15%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1865915Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at G2/M phase at 1 nM after 24 hrs
AID1395070Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
AID1167561Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID1220791Ratio of drug level in blood to plasma in monkey2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1572959Induction ERalpha degradation in human MCF7 cells assessed as suppression of pGR mRNA levels up to 300 nM by qRT-PCR analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
AID288626Displacement of [3H]estradiol from human recombinant ERbeta relative to estradiol2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID70354Transcriptional activation in HeLa cells expressing human Estrogen receptor alpha; No data2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID1215350Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined CYP450 IC50 s2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
A refined cytochrome P540 ICâ‚…â‚€ shift assay for reliably identifying CYP3A time-dependent inhibitors.
AID1807417Uncompetitive type inhibition of human AOX assessed as inhibition constant using phthalazine as substrate preincubated for 30 mins followed by substrate addition by HPLC-MS analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case.
AID248083Inhibition of estrogen-mediated human breast adenocarcinoma (MCF-7) cell proliferation2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID70656Ability to displace [3H]17-beta-estradiol from Estrogen receptor beta by scintillation proximity assay.2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
2-Amino-4,6-diarylpyridines as novel ligands for the estrogen receptor.
AID1752648Antiproliferative activity against ER-negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay2021Bioorganic & medicinal chemistry, 10-01, Volume: 47Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities.
AID1220240Unbound fraction during CYP4500-mediated metabolism in human intestinal microsomes2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID265000Binding affinity to ERbeta2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID1220257Ratio of drug level in blood to plasma in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1053264Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1598615Osteogenic activity in ovariectomized-induced C57BL/6 mouse model of osteoporosis assessed as recovery of tibia weight at 1 mg/kg, sc administered 6 days per week for 70 days relative to control2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Antisulfatase, Osteogenic, and Anticancer Activities of Steroid Sulfatase Inhibitor EO-33 in Mice.
AID471242Agonist activity at estrogen receptor in human MCF7 cells assessed as 17-beta-estradiol-induced cell proliferation at 10 uM after 24 hrs by [14C]thymidine incorporation assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID179989In vivo prevention of reduced serum cholesterol in ovariectomised rats on oral administration1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
AID590269Clearance in mouse2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID70507Inhibition of [3H]17-beta-estradiol binding to human recombinant Estrogen receptor beta.2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID590267Intrinsic clearance in human liver microsomes in presence of NADPH2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID242959Selectivity ratio for binding to ER beta and ER alpha receptors2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains.
AID1202404Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as mineral apposition rate at 5 mg/kg/day, po administered six times a week for 3 months by fluorescence assay (Rvb = 1.06 +/- 0.27 micrometer/day)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID387084Displacement of [3H]estradiol from full length biotinylated human ERbeta by scintillation proximity assay2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Synthesis of 3-alkyl naphthalenes as novel estrogen receptor ligands.
AID498477Inhibition of PLD1 in human Calu-1 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1184075Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1865934Toxicity in female Wistar rat xenografted with methyl nitroso urea (MNU)-preinduced breast cancer assessed as reduction in breast epithelial density at 5 mg/kg, po
AID251389Percent cholesterol reduction in female ovariectomized rat at 1.5 mg/kg (for 6 weeks)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs.
AID1215347Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by LC-MS/MS analysis in 2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
A refined cytochrome P540 ICâ‚…â‚€ shift assay for reliably identifying CYP3A time-dependent inhibitors.
AID1752632Antiproliferative activity against ER-positive human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay2021Bioorganic & medicinal chemistry, 10-01, Volume: 47Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1865905Downregulation of hERE gene transcription expression in human MCF7 cells at 0.1 to 1 nM measured by luciferase reporter gene assay
AID1865897Antagonist activity at ERalpha in human MCF7 cells assessed as inhibition of p-ERK1/2 activation at 0.1 to 1 nM measured after 24 hrs by Western blot analysis
AID1283251Inhibition of C-24 reductase in Dhcr7-deficient mouse Neuro2a cells assessed as increase in zymosterol levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1601168Binding affinity to human C5a assessed as induction of conformational change with no shift in absorption maxima at 1 uM by fluorescence analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1317231Cytotoxicity against human Saos2 cells assessed as reduction in cell proliferation at 5 to 10 uM after 7 days by MTS assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Discovery of a sulfamate-based steroid sulfatase inhibitor with intrinsic selective estrogen receptor modulator properties.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1167565Antitumor activity against mouse 4T1 cells allografted in BALB/c mouse assessed as tumor growth inhibition at 15 mg/kg, ip administered 24 hrs post tumor implantation on even days of total 9 doses for 18 days measured after 18 days relative to control2014European journal of medicinal chemistry, Nov-24, Volume: 87Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
AID590262Intrinsic clearance in dog gut microsomes in presence of UGT2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1865917Lipophilicity, logD of the compound by shake-flask method
AID189005Percent protection of bone mineral density in the distal femur of OVX rat at a dose of 0.1 mg/kg/day1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID1598618Osteogenic activity in ovariectomized-induced C57BL/6 mouse model of osteoporosis assessed as recovery of tibia calcium content at 1 mg/kg, sc administered 6 days per week for 70 days by Triple Quad ICP-MS analysis relative to control2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Antisulfatase, Osteogenic, and Anticancer Activities of Steroid Sulfatase Inhibitor EO-33 in Mice.
AID242722Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor alpha; ERE assay2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1283264Inhibition of delta 8-7 isomerase in human SLOS fibroblasts assessed as decrease in 7-DHC levels at 10 nM after 5 days by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID176940Dose required to reduce serum cholesterol by 50% relative to OVX controls was determined (in vivo)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID1693904Effect on cell cycle distribution in human MCF7 cells assessed as accumulation of cells at G2/M phase at IC50 incubated for 72 hrs by PI staining based flow cytometry analysis2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID430510Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecula formation surface at 5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1752633Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay2021Bioorganic & medicinal chemistry, 10-01, Volume: 47Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities.
AID1865894Antagonist activity at progesterone receptor in human MCF7 cells
AID1276575Antiproliferative activity against tamoxifen resistant human MCF7:5C cells assessed as inhibition of cell growth at 10 nM after 9 days by MTS assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
AID503305Antiproliferative activity against human PC3 cells at 500 nM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID252865Percent agonism of estradiol effects in rat uterine tissue at 1 mg/kg2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains.
AID1202344Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as lymph level at 5 mg/kg/day, po administered six times a week for 3 months (Rvb = 50.35 +/- 12.96%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID242043Inhibition of [3H]estradiol binding to human estrogen receptor beta expressed in HeLa cells2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID1283252Inhibition of C-24 reductase in Dhcr7-deficient mouse Neuro2a cells assessed as increase in desmosterol levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1317229Agonist activity at ERalpha in human Saos2 cells assessed as induction of cell proliferation at 1 uM after 7 days by MTS assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Discovery of a sulfamate-based steroid sulfatase inhibitor with intrinsic selective estrogen receptor modulator properties.
AID244486Bone mineral density of sham type raloxifene was determined in vivo against estrogen receptor alpha2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
AID1276576Antiproliferative activity against tamoxifen resistant human MCF7:5C cells assessed as inhibition of cell growth at 100 nM after 9 days by MTS assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
AID1572960Induction ERalpha degradation in human MCF7 cells assessed as suppression of GREB1 mRNA levels up to 300 nM by qRT-PCR analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
AID1276566Agonist activity at estrogen receptor alpha in human MCF7:WS8 cells after 18 hrs by dual luciferase reporter assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
AID590275Bioavailability in dog2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
AID1693875Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID173696Percent decrease in serum cholesterol relative to OVX control at 10 mg/kg in rat was determined (in vivo)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID265004Agonist activity at estrogen receptor in MCF7 cells at 10 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID69075Binding affinity for Estrogen receptor in MCF-Cells relative to estradiol1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanone.
AID1301300Down regulation of ERalpha in human MCF7 cells at 10 uM after 6 hrs by Western blot analysis2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator.
AID250282Bone mineral density of DFM:central in female ovariectomized rats at 1.5 mg/kg (for 6 weeks)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs.
AID1272981Binding affinity to hound bone powder assessed as reduction in bound compound level at 50 uM after 16 hrs by NMR spectroscopic analysis relative to alendronate2016Bioorganic & medicinal chemistry, 02-15, Volume: 24, Issue:4
Structural features underlying raloxifene's biophysical interaction with bone matrix.
AID241201Inhibition of estrogen receptor beta2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
AID241865Inhibition of binding to recombinant human estrogen receptor beta2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.
AID1594508Antagonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as reduction in E2-induced ER-alpha-mediated transcriptional activity by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1739452Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as increase in thickness of trabeculae at 5 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID1865904Downregulation of hERE gene transcription expression in human MCF7 cells at 0.1 to 1 nM measured by luciferase reporter gene assay
AID1865909Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at G0/G1 phase at 1 nM after 24 hrs
AID1558989Antiproliferative activity against human MCF7:WS8 cells assessed as reduction in cell viability incubated for 5 days by Hoechst 33258 dye based assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
AID103918Inhibition of 17-beta-estradiol (10e-11 M) mediated MCF-7 cell proliferation1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Synthesis and biological activity of trans-2,3-dihydroraloxifene.
AID1082235Inhibition of Homo sapiens (human) aldehyde oxidase2011Journal of agricultural and food chemistry, May-11, Volume: 59, Issue:9
Neonicotinoid insecticides: oxidative stress in planta and metallo-oxidase inhibition.
AID1220787Fraction unbound in dog plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1865887Relative binding affinity to ERalpha (unknown origin)
AID471238Displacement of radiolabeled estrogen from estrogen receptor alpha by scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID669596Binding affinity to ERalpha ligand binding domain2012ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3
Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs.
AID755455Antagonist activity at human GTS-tagged FXR at 15 uM after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1598623Hepatotoxicity in ovariectomized-induced C57BL/6 mouse model of osteoporosis assessed as effect on liver weight at 1 mg/kg, sc administered 6 days per week for 70 days measured post last dose by necropsy analysis2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Antisulfatase, Osteogenic, and Anticancer Activities of Steroid Sulfatase Inhibitor EO-33 in Mice.
AID102776Agonist activity in MCF-7 breast tumor cell proliferation assay, based on pS2 gene expression at 10 uM2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.
AID265001Inhibition of estrogen receptor in Ishikawa cells2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID1601161Binding affinity to human C5a assessed as dissociation constant after 1 hr by circular dichroism analysis2019Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19
A rational search for discovering potential neutraligands of human complement fragment 5a (
AID1865888Relative binding affinity to ERbeta (unknown origin)
AID397671Cytotoxicity against estrogen receptor deficient human MDA-MB-231 cells at 25 uM after 72 hrs by MTS assay2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor beta.
AID70673Binding to Estrogen receptor- beta (ER beta) receptor2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.
AID628348Antiestrogenic activity in human ER-positive MCF7 cells assessed as inhibition of 17beta estradiol-induced secreted alkaline phosphatase activity at 2 nM after 48 hrs by phospha-light reporter chemiluminescence assay2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Using the pER8:GUS reporter system to screen for phytoestrogens from Caesalpinia sappan.
AID1866708Binding affinity to human recombinant ERalpha by competitive fluorometric binding assay2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.
AID471536Effect on bone turnover in ovariectomized rat assessed as prevention of tibial bone density at 1 mg/kg, po administered daily measured after 6 weeks by ex vivo peripheral quantitative computerized tomography2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID1676124Selectivity index, ratio of CC50 for human A549 cells to IC50 for antiviral activity against pseudotyped Marburgvirus-Musoke infected in human A549 cells2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID242966IC50 ratio of binding to estrogen receptor beta and alpha2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
AID1693881Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1163061Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1693894Induction of apoptosis in human MCF7 cells assessed as viable cells at IC50 incubated for 72 hrs by Annexin V/FITC and PI staining based flow cytometry analysis (Rvb = 90.6 +/- 0.4 %)2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID501528Selectivity ratio of IC50 for human wild type ERbeta to IC50 for human ERbeta E305A mutant2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements.
AID69056In vitro relative binding affinity by competition with [3H]17-beta-estradiol for estrogen receptor in MCF-7 cell lysate1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
AID1693878Therapeutic index, ratio of CC50 for human HSF cells to IC50 for ER and PR-positive human MCF7 cells2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis, antitumor activity and structure-activity studies of novel pyridoxine-based bioisosteric analogs of estradiol.
AID1797995ER-alpha Radioligand Binding Assay and ERE-Luciferase Reporter Assay. from Article 10.1021/jm015577l: \\Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.\\2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID1797996ER-beta Radioligand Binding Assay and ERE-Luciferase Reporter Assay. from Article 10.1021/jm015577l: \\Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.\\2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID1801138In vivo Deuterated 1-Butanol PLD Assay from Article 10.1021/cb500828m: \\Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.\\2015ACS chemical biology, Feb-20, Volume: 10, Issue:2
Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.
AID1799395PLD1 In Vitro Enzymatic Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1797989ER-alpha Radioligand Binding Assay and ERE-Luciferase Reporter Assay. from Article 10.1021/jm030086h: \\Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.\\2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
AID1801141Exogenous PldA Assay from Article 10.1021/cb500828m: \\Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.\\2015ACS chemical biology, Feb-20, Volume: 10, Issue:2
Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.
AID1797853Estrogen Receptor Binding Assay. from Article 10.1021/jm070079j: \\Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.\\2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
AID1797926Estrogen Receptor Binding Assay and Ishikawa Assay from Article 10.1021/jm050723z: \\A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.\\2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
AID1797992ER-alpha Radioligand Binding Assay and ERE-Luciferase Reporter Assay. from Article 10.1021/jm040858p: \\Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective 2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
AID1799398293-PLD2 Cell-Based Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1799396d.311 Enzymatic Inhibition Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1799399PLD2 In Vitro Enzymatic Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1799397Calu-1 Cell-Based Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346845Human Estrogen receptor-alpha (3A. Estrogen receptors)2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists.
AID1346880Human Estrogen receptor-beta (3A. Estrogen receptors)2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
2-Amino-4,6-diarylpyridines as novel ligands for the estrogen receptor.
AID1345880Human GPER (G protein-coupled estrogen receptor)2013Obstetrics and gynecology international, , Volume: 2013G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth.
AID1346845Human Estrogen receptor-alpha (3A. Estrogen receptors)1997Endocrinology, Mar, Volume: 138, Issue:3
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (127)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.79)18.7374
1990's7 (5.51)18.2507
2000's46 (36.22)29.6817
2010's57 (44.88)24.3611
2020's16 (12.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 98.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index98.60 (24.57)
Research Supply Index4.86 (2.92)
Research Growth Index5.69 (4.65)
Search Engine Demand Index174.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (98.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews8 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other120 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]